2016 Revision of WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, Non-Hematopathologist, (Part 2 of 2)
This is a review of the most important changes to the WHO hematopathology classification system as part of the 2016 revision. Emphasis will be placed on presenting the information so that it is relevant and understandable by non-hematopathologists and laboratory staff. This will be a two-part presentation, with the first lecture covering lymphoid neoplasms and the second presentation covering myeloid and precursor neoplasms. September 15, 2016 was part one of the series.
- Understand the need for the 2016 revision to the 2008 WHO hematopathology classification system.
- Review pertinent changes involving lymphoid neoplasms in a manner understandable by general pathologists and laboratory staff.
- Illustrate important situations where advanced testing (e.g. IHC, molecular, FISH) may be helpful in further distinguishing hematopoietic neoplasms, which had been difficult to classify or confirm with certainty in the past.
If you have viewed this educational webinar, training or tutorial on Knowledge Pathway and would like to apply for continuing education credits with your certifying organization, please download the form to assist you in adding self-reported educational credits to your transcript.Apply for self-reported educational credits
For the use of any product, the applicable product documentation, including information guides, inserts and operation manuals should be consulted. Leica Biosystems and the editors hereby disclaim any liability arising directly or indirectly from the use of the content, including from any drugs, devices, techniques or procedures described in the content.
Copyright © 2020 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.